Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report

A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with vertebral and chest wall invasion that successfully und...

Full description

Saved in:
Bibliographic Details
Main Authors: Kei Kunimasa, MD, PhD, Jiro Okami, MD, PhD, Satoshi Takenaka, MD, PhD, Keiichiro Honma, MD, PhD, Yoji Kukita, PhD, Shigenori Nagata, MD, PhD, Takahisa Kawamura, MD, PhD, Takako Inoue, MD, Motohiro Tamiya, MD, Hanako Kuhara, MD, PhD, Kazumi Nishino, MD, PhD, Hideaki Tahara, MD, PhD, Toru Kumagai, MD, PhD
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
SMARCA4-deficient undifferentiated tumor
Conversion surgery
Neoadjuvant therapy
Immunotherapy
Case report
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/6fce6fc2448440c289bbd4912081d54c
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/6fce6fc2448440c289bbd4912081d54c

Similar Items